ImmuCell Corporation (ICCC)

Market Cap	49.40M
Revenue (ttm)	26.49M
Net Income (ttm)	-2.16M
Shares Out	8.98M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,337
Open	5.50
Previous Close	5.50
Day's Range	5.50 - 5.50
52-Week Range	3.34 - 5.82
Beta	0.39
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2025

About ICCC

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Masti...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 1987
• Employees: 75
• Stock Exchange: NASDAQ
• Ticker Symbol: ICCC
• Website: https://immucell.com

Financial Performance

In 2024, ImmuCell's revenue was $26.49 million, an increase of 51.64% compared to the previous year's $17.47 million. Losses were -$2.16 million, -62.65% less than in 2023.